| Home : Reistone Biopharma Announces Positive Topline Results from Phase 2 Clinical Trial Evaluating SHR0302, a JAK1 Inhibitor for the Treatment of Moderate-to-Severe Atopic Dermatitis |
|
Oct 26
2020 |
Reistone Biopharma Announces Positive Topline Results from Phase 2 Clinical Trial Evaluating SHR0302, a JAK1 Inhibitor for the Treatment of Moderate-to-Severe Atopic Dermatitis |
|
SHR0302 monotherapy achieved positive results on reaching primary endpoints with statistical significance, delivering significant improvements in skin clearance Both doses were shown to be superior to placebo for key secondary endpoints AEs were manageable and generally transient and... |
|
|
|
| Source:https://www.prnewswire.com:443/news-releases/reistone-biopharma-announces-positive-topline-results-from-phase-2-clinical-trial-evaluating-shr0302-a-jak1-inhibitor-for-the-treatment-of-moderate-to-severe-atopic-dermatitis-301159478.html |
| |
|
Related News
|
» Llega el tráiler oficial para el nuevo documental sobre la marca Johnnie Walker del director Anthony Wonke, ganador de varios premios BAFTA
» Stephen Scoggins: Advice For Business Owners After COVID-19
|
